Detalhe da pesquisa
1.
Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1).
Int J Cancer
; 148(3): 682-691, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33405269